Press Releases

DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14

VANCOUVER, British Columbia and MENLO PARK, Calif., July 13, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company will ring the Nasdaq Opening Bell on Thursday, July 14 in honor of its recent listing on Nasdaq. Members of the DelMar Pharmaceuticals corporate team including Jeffrey Bacha, Chairman and CEO, will ring the opening bell in celebration of the listing.

DelMar Pharmaceuticals Logo

"This uplisting to Nasdaq is a milestone achievement for the Company, and one that we believe presents the opportunity for exposure to a broader and more diverse investor audience," said Jeffrey Bacha, DelMar's Chairman and CEO. "We would like to take this moment to thank and acknowledge the employees, investors, and partners who have supported the Company and helped facilitate this day. Due to strong scientific leadership coupled with this increased visibility on a senior exchange, we believe we are well-positioned for future growth and recognition among security holders."

A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live - The ceremony will begin at approximately 9:20am EST.

The Company began trading on the Nasdaq Capital Market on July 12, 2016

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

DelMar has been conducting a Phase I/II clinical trial with VAL-083 as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  DelMar provided an update on this ongoing trial at AACR confirming that results to date support the potential of a VAL-083 to offer a clinically meaningful survival benefit and a promising new treatment option for GBM patients who have failed or are unlikely to respond to currently available chemotherapeutic regimens.  The Company anticipates meeting with the FDA in the first half of 2016 to discuss a proposed registration-directed Phase III protocol and data from its current clinical trial with a goal of advancing VAL-083 into registration-directed clinical trials for GBM patients who have failed temozolomide and bevacizumab.

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Investor Relations Counsel:  Amato & Partners LLC.

For media relations:

Eric Fischgrund
646-699-1414
eric@fischtankpr.com

About Nasdaq

Nasdaq is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Logo - https://photos.prnewswire.com/prnh/20150909/265198LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-ring-the-nasdaq-stock-market-opening-bell-on-july-14-300297850.html

SOURCE DelMar Pharmaceuticals, Inc.